Access these resources to learn more about the latest long-term outcomes data for larotrectinib in CNS and GI cancers, and to access an overview of the TAPISTRY platform trial. Prof Andrea Sartore-Bianchi (NTRK CONNECT) has developed this resource with COR2ED.

Hello I’m Andrea Sartore-Bianchi, a medical oncologist at Niguarda Hospital and University of Milan, Italy.

And I’m glad to provide you with this update about data regarding NTRK fusions as target of therapy from recent ASCO and World Congress on Gastrointestinal Cancer 2021.

There is indeed always interest around this agnostic target of cancer therapy and some relevant updates and new analysis have been presented in both congresses with a particular focus also on GI cancers.

First of all, at ASCO 21 an updated efficacy analysis for larotrectinib has been presented with a two years efficacy and safety follow up of the integrated data set from the three phase 1 and 2 trials previously presented. Now the total number of patients is more than 200, mainly sarcomas but also 5% colorectal cancer.

The main message from this data is that the majority of patients with TRK fusion cancer treated with larotrectinib had a long-term clinical benefit with very durable responses in PFS and OS and the safety profile continued to be favourable.

In this data set there were no CNS primary tumours but at the same congress, ASCO 2021, Dr Perreault presented data, instead of larotrectinib in the specific population of primary CNS tumour, and this is another important population, given the efficacy that we know that NTRK inhibitor has also in this setting.

In this analysis tumours were mainly high grade gliomas and also in this population larotrectinib induced tumour shrinkage in the majority of patients and rapid and durable responses with a high disease control rate and a favourable safety profile.

Now turning to the World Congress of Gastrointestinal Cancer, here we had presented by Dr Boni an interesting updated analysis on an expanded data set of GI tumours treated with larotrectinib. 18 patients had been presented and mostly presented with colorectal cancer. And now in colorectal cancer these patients were mainly MSI-high because it has been well confirmed, and now we know, that there is an enrichment for NTRK fusion in colorectal cancer that are RAS, BRAF wild type, MSI-high and MLH1 methylated. So these are those sporadic MSI-high tumours, and in this analysis, there were also cholangiocarcinoma and pancreatic cancer.

So the overall response rate has been confirmed to be 40% up to 50% in colorectal cancer and also here in this tumour type a complete response has been observed. The overall survival in the colorectal cancer cohort were also very long, approaching 30 months. And it is important to understand if this patient received also immunotherapy, being for the most part of them also MSI-high.

Finally, it should be mentioned that, at the ASCO Congress, also the trial design of the TAPISTRY trial is being presented by Dr Drilon. This is a novel platform, a phase 2 umbrella trial with target therapy or immunotherapy based on relevant oncogenic alterations and there is indeed a cohort of NTRK positive patients to be treated with entrectinib.

So overall, there is an interest, and these recent presentations highlight, I think, the importance of testing for NTRK gene fusions in patients with cancer. The majority of patients with this molecular alteration had long-term clinical benefit.  With TRK inhibitors there are also data regarding GI tumours now in particular MSI colorectal cancer. And this, I think, can add a valuable target also in this tumour type, in this specific subpopulation.

I thank you very much for your attention and I encourage you to visit the NTRK CONNECT website where you can find also a complete slide deck with all these presentations from ASCO and World Congress on Gastrointestinal Cancer, thank you.

This programme is supported by an Independent Educational Grant from Bayer

Dr Andrea Sartore-Bianchi is head of Clinical Molecular Oncology at the Department of Hematology & Oncology, Niguarda Cancer Center, Milano, Italy. He completed his medical degree at the University of Pavia in 1999, and undertook specialist training at IRCCS Policlinico San Matteo. After completing his doctoral studies, he conducted preclinical research at the Division of Clinical Pharmacology and Experimental Cancer Therapeutics in the Department of Medicine at Brown University, Rhode Island, USA. Dr Sartore-Bianchi’s main clinical and research interests include the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to molecular-targeted therapies and on the epidermal growth factor receptor signal transduction pathway. He is principal and co-investigator in Phase I-II-III clinical trials for gastrointestinal malignancies, and first author of research articles in the Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research and PLoS One. Currently, he is adjunct Professor for the School of Specialization in Oncology and Pharmacology at the University of Milano. He has been listed among the top 30 authors of primary research papers on cancer.

Prof. Andrea Sartore-Bianchi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Bayer, Sanofi and Servier Pharmaceuticals. 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

Brought to you by

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from AstraZeneca, Amoy Diagnostics and Bayer.

Meet the experts

Other programmes of interest

Breast-Cancer-Connect-ER-HER2-low-thumbnail-BR2310 Tweetorial
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Journey through a patient case from testing and diagnosis to treatment and AE management

Dr Aditya Bardia
Endorsed by
  • clock 11 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
NSCLC-perseverance-pays-off- thumbnail-PO2305 Podcast
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Conference update
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
mCRC: Optimising patient outcomes with late-line treatment

Maximising outcomes for patients with advanced CRC

Assoc. Prof. Gerald Prager, Dr Victor Hugo Fonseca de Jesus
Endorsed by
Digestive Cancers Europe 5th anniversary
  • download Downloadable
  • clock 23 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Lung cancer expert panel Conference update
ESMO 2023: Lung cancer update

Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.